| Autor: |
Green JA; Pacific Biotechnology Ltd., Rushcutters Bay, N.S.W., Australia., Smith GM, Buchta R, Lee R, Ho KY, Rajkovic IA, Scott KF |
| Jazyk: |
angličtina |
| Zdroj: |
Inflammation [Inflammation] 1991 Oct; Vol. 15 (5), pp. 355-67. |
| DOI: |
10.1007/BF00917352 |
| Abstrakt: |
Elevation of circulating phospholipase A2 (PLA2) activity is associated with sepsis and septic shock. Elevated levels of PLA2 activity also are seen in association with chronic inflammatory disorders such as rheumatoid arthritis. The relationship between these phospholipases is unclear. We have developed a highly specific enzyme-linked immunosorbent assay (ELISA) capable of measuring human synovial PLA2 in plasma, using monoclonal antibodies raised to recombinant synovial PLA2. This ELISA has been used to quantitate circulating PLA2 levels in patients clinically diagnosed with sepsis. These elevated levels positively correlated with the elevation seen in plasma PLA2 enzyme activity. The antibodies also have been used to purify immunoreactive PLA2 from plasma of patients with sepsis, thus enabling characterization of the purified protein by amino-terminal sequence analysis. We conclude from this study that the increase in PLA2 activity seen in association with sepsis and septic shock results from a dramatic elevation in levels of a circulating PLA2 enzyme. This inflammatory PLA2 is indistinguishable, both immunologically and chemically, from that associated with rheumatoid arthritis. Therapeutic agents directed towards inhibition of this inflammatory PLA2 enzyme may have utility in the treatment of both chronic and acute inflammatory disease. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink